Related Experiment Videos

Platelet monoamine oxidase B activity in dementia. A 4-year follow-up

M E Götz1, P Fischer, W Gsell

  • 1Department of Psychiatry, University of Würzburg, Germany.

Insights

Platelet monoamine oxidase B (MAO-B) activity rises in Alzheimer's patients over time. This increase in MAO-B does not correlate with cognitive decline, suggesting it may reflect later-stage neurodegeneration.

Area of Science:

  • Neuroscience
  • Biochemistry
  • Gerontology

Background:

  • Elevated platelet monoamine oxidase B (MAO-B) activity is observed in patients with dementia.
  • Alzheimer's disease (DAT) is a progressive neurodegenerative disorder characterized by cognitive decline.

Purpose of the Study:

  • To investigate the longitudinal relationship between platelet MAO-B activity and cognitive function (Mini-Mental State - MMS) in patients with probable dementia of the Alzheimer type (DAT).
  • To establish a 4-year follow-up of MAO-B activity and MMS scores in DAT patients and age-matched controls.

Main Methods:

  • A 4-year longitudinal study involving patients with probable DAT and age-matched healthy controls.
  • Measurement of platelet monoamine oxidase B (MAO-B) activity.
  • Assessment of cognitive function using the Mini-Mental State (MMS) examination.
  • Statistical analysis including Spearman rank correlation to assess relationships between variables.

Main Results:

  • Platelet MAO-B activity significantly increased in DAT patients compared to controls starting from year 2 and remained elevated throughout the 4-year study period (p < 0.0001).
  • The decline in MMS scores did not correlate with the time course of increasing platelet MAO-B activity.
  • Cognitive decline (decrease in MMS scores) was observed to precede the elevation of platelet MAO-B activity in DAT patients.

Conclusions:

  • Increased platelet MAO-B activity is a significant longitudinal finding in probable Alzheimer's disease.
  • The observed elevation in MAO-B activity does not directly correlate with the rate of cognitive decline, suggesting it may not be an early marker of cholinergic system degeneration.
  • Elevated MAO-B activity might reflect degenerative processes in monoaminergic systems occurring at later stages of Alzheimer's disease.

Related Concept Videos